Insider · CIK 0001134655
Ansbert Gadicke
Files at TRDA (Entrada Therapeutics, Inc.), HOWL (Werewolf Therapeutics, Inc.), ITOS (iTeos Therapeutics, Inc.), AKTS (Aktis Oncology, Inc.). First filing Apr 30, 2025, latest Jan 14, 2026.
In brief
Ansbert Gadicke files SEC Form 4 as 10% owner at HOWL (Werewolf Therapeutics, Inc.), and also at ITOS (iTeos Therapeutics, Inc.), AKTS (Aktis Oncology, Inc.), TRDA (Entrada Therapeutics, Inc.). Since Apr 30, 2025, Ansbert Gadicke has reported 1 open-market buy worth $20M and 11 open-market sells worth $11M, the latest filed on Jan 14, 2026.
A track record needs three past buys with six months of prices behind them; Ansbert Gadicke has 0, so none is measured yet.
The newest scored trade: bought $20M of AKTS on Jan 12, 2026, filed Jan 14, 2026, scored 60 (notable). In the last 12 months: 1 buy worth $20M and 9 sells worth $2.2M.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
HOWL: Werewolf Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
AKTS: Aktis Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | Aktis Oncology, Inc. | $20M 1,112,777 shares | +12% | 0% from low-3% from high | |
| 15Weak | Werewolf Therapeutics, Inc. | $183k 199,732 shares | -4% | - | |
| 18Weak | Werewolf Therapeutics, Inc. | $137k 141,927 shares | -3% | - | |
| 19Weak | Werewolf Therapeutics, Inc. | $180k 195,666 shares | -4% | - | |
| 18Weak | Werewolf Therapeutics, Inc. | $148k 160,103 shares | -3% | - | |
| 19Weak | Werewolf Therapeutics, Inc. | $201k 209,652 shares | -4% | - | |
| 20Weak | Werewolf Therapeutics, Inc. | $241k 213,529 shares | -4% | - | |
| 21Weak | Werewolf Therapeutics, Inc. | $296k 242,890 shares | -4% | - | |
| 23Weak | Werewolf Therapeutics, Inc. | $392k 295,043 shares | -5% | - | |
| 24Weak | Werewolf Therapeutics, Inc. | $446k 276,017 shares | -4% | - | |
| 53Moderate | iTeos Therapeutics, Inc. | $8.3M 1,031,931 shares | -23% | - | |
| 27Weak | Werewolf Therapeutics, Inc. | $4,605 4,386 shares | -0% | - |
Transactions
Every row this insider has filed, 40 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +1,314,262 | - | - | 1,655,971 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +5,914,197 | - | - | 7,570,168 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +1,577,119 | - | - | 9,147,287 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +1,112,777 | $18.00 | $20M | 10,260,064 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series Seed Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -5,000,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -22,500,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -6,000,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Dec 2, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -59,277 | $0.89 | $53k | 4,924,566 | Dec 4, 2025 |
| Dec 3, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -57,225 | $0.87 | $50k | 4,867,341 | Dec 4, 2025 |
| Dec 4, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -83,230 | $0.97 | $81k | 4,784,111 | Dec 4, 2025 |
| Nov 26, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -60,733 | $0.98 | $60k | 5,065,037 | Dec 1, 2025 |
| Nov 28, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -20,277 | $0.99 | $20k | 5,044,760 | Dec 1, 2025 |
| Dec 1, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -60,917 | $0.94 | $57k | 4,983,843 | Dec 1, 2025 |
| Nov 21, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -64,331 | $0.83 | $53k | 5,257,105 | Nov 25, 2025 |
| Nov 24, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -88,802 | $0.98 | $87k | 5,168,303 | Nov 25, 2025 |
| Nov 25, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -42,533 | $0.92 | $39k | 5,125,770 | Nov 25, 2025 |
| Nov 18, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -52,627 | $0.93 | $49k | 5,428,912 | Nov 20, 2025 |
| Nov 19, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -66,324 | $0.94 | $62k | 5,362,588 | Nov 20, 2025 |
| Nov 20, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -41,152 | $0.89 | $37k | 5,321,436 | Nov 20, 2025 |
| Nov 13, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -90,951 | $0.98 | $89k | 5,600,240 | Nov 17, 2025 |
| Nov 14, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -61,640 | $0.93 | $57k | 5,538,600 | Nov 17, 2025 |
| Nov 17, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -57,061 | $0.95 | $54k | 5,481,539 | Nov 17, 2025 |
| Nov 7, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -68,480 | $1.11 | $76k | 5,836,240 | Nov 12, 2025 |
| Nov 10, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -48,570 | $1.18 | $57k | 5,787,670 | Nov 12, 2025 |
| Nov 11, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -55,810 | $1.14 | $64k | 5,731,860 | Nov 12, 2025 |
| Nov 12, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -40,669 | $1.09 | $44k | 5,691,191 | Nov 12, 2025 |
| Nov 4, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -140,488 | $1.22 | $171k | 6,007,122 | Nov 6, 2025 |
| Nov 5, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -47,950 | $1.22 | $58k | 5,959,172 | Nov 6, 2025 |
| Nov 6, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -54,452 | $1.21 | $66k | 5,904,720 | Nov 6, 2025 |
| Oct 30, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -86,936 | $1.43 | $124k | 6,355,717 | Nov 3, 2025 |
| Oct 31, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -114,044 | $1.28 | $146k | 6,241,673 | Nov 3, 2025 |
| Nov 3, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -94,063 | $1.29 | $121k | 6,147,610 | Nov 3, 2025 |
| Oct 27, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -72,709 | $1.72 | $125k | 6,645,961 | Oct 29, 2025 |
| Oct 28, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -69,068 | $1.64 | $113k | 6,576,893 | Oct 29, 2025 |
| Oct 29, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -134,240 | $1.55 | $208k | 6,442,653 | Oct 29, 2025 |
| May 13, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote | -1,031,931 | $8.06 | $8.3M | 3,452,797 | May 15, 2025 |
| Mar 27, 2025 | HOWL Werewolf Therapeutics, Inc. | XIn-the-money exercise Common Stockindirect: See Footnote | +50,873 | $0.09 | $4,579 | 6,723,056 | Apr 30, 2025 |
| Mar 27, 2025 | HOWL Werewolf Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnote | -4,386 | $1.05 | $4,605 | 6,718,670 | Apr 30, 2025 |
| Mar 27, 2025 | HOWL Werewolf Therapeutics, Inc. | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: See Footnote | -8,031 | $0.00 | $0 | 0 | Apr 30, 2025 |
| Mar 27, 2025 | HOWL Werewolf Therapeutics, Inc. | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: See Footnote | -42,842 | $0.00 | $0 | 0 | Apr 30, 2025 |
Questions about Ansbert Gadicke
Answered from the filings on this page, as of the latest one.
Is Ansbert Gadicke buying or selling?
In the last 12 months Ansbert Gadicke reported 1 open-market buy worth $20M and 9 open-market sells worth $2.2M on SEC Form 4; the latest was bought $20M of AKTS on Jan 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Ansbert Gadicke's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ansbert Gadicke has 0.
Where does Ansbert Gadicke file Form 4?
Ansbert Gadicke has filed Form 4 at HOWL (Werewolf Therapeutics, Inc.); ITOS (iTeos Therapeutics, Inc.); AKTS (Aktis Oncology, Inc.); TRDA (Entrada Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.